PriceTargets.com logo

Immunocore - IMCR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $79.13
  • Forecasted Upside: 30.12%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$60.81 As of 01/27/2023 10:59 AM ET
▲ +0.14 (0.23%)

This chart shows the closing price for IMCR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Immunocore Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMCR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMCR

Analyst Price Target is $79.13
▲ +30.12% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Immunocore in the last 3 months. The average price target is $79.13, with a high forecast of $90.00 and a low forecast of $67.00. The average price target represents a 30.12% upside from the last price of $60.81.

This chart shows the closing price for IMCR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 polled investment analysts is to buy stock in Immunocore.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/28/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2023

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/16/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$33.00 ➝ $80.00Low
11/30/2022BarclaysInitiated CoverageOverweight$80.00Low
11/21/2022HC WainwrightBoost TargetBuy$80.00 ➝ $90.00Low
11/10/2022Morgan StanleyBoost TargetOverweight$72.00 ➝ $79.00Low
10/13/2022Morgan StanleyLower TargetOverweight$77.00 ➝ $72.00Low
9/14/2022JPMorgan Chase & Co.Boost TargetOverweight$60.00 ➝ $67.00Low
9/9/2022Morgan StanleyInitiated CoverageOverweight$77.00Low
9/8/2022LADENBURG THALM/SH SHInitiated CoverageBuy$82.00Low
8/8/2022CowenInitiated CoverageOutperformLow
8/8/2022CowenInitiated CoverageOutperform$70.00Low
8/2/2022BTIG ResearchInitiated CoverageBuy$85.00Low
7/5/2022HC WainwrightReiterated RatingBuy$80.00N/A
2/8/2022HC WainwrightInitiated CoverageBuy$80.00High
10/19/2021OppenheimerInitiated CoverageOutperform$56.00Medium
3/2/2021JPMorgan Chase & Co.Initiated CoverageOverweight$58.00Medium
3/2/2021Jefferies Financial GroupInitiated CoverageBuy$65.00Medium
3/2/2021The Goldman Sachs GroupInitiated CoverageNeutral$40.00Medium
(Data available from 1/27/2018 forward)

News Sentiment Rating

0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/1/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/31/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/30/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2022
  • 5 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2022
  • 5 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/28/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2023

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Immunocore logo
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Read More

Today's Range

Now: $60.81
Low: $60.81
High: $60.81

50 Day Range

MA: $59.04
Low: $51.43
High: $64.21

52 Week Range

Now: $60.81
Low: $20.02
High: $69.06

Volume

1,038 shs

Average Volume

291,208 shs

Market Capitalization

$2.67 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55

Frequently Asked Questions

What sell-side analysts currently cover shares of Immunocore?

The following Wall Street sell-side analysts have issued stock ratings on Immunocore in the last twelve months: Barclays PLC, BTIG Research, Cowen Inc, Cowen Inc., HC Wainwright, JPMorgan Chase & Co., LADENBURG THALM/SH SH, Morgan Stanley, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for IMCR.

What is the current price target for Immunocore?

8 Wall Street analysts have set twelve-month price targets for Immunocore in the last year. Their average twelve-month price target is $79.13, suggesting a possible upside of 30.4%. HC Wainwright has the highest price target set, predicting IMCR will reach $90.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $67.00 for Immunocore in the next year.
View the latest price targets for IMCR.

What is the current consensus analyst rating for Immunocore?

Immunocore currently has 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMCR will outperform the market and that investors should add to their positions of Immunocore.
View the latest ratings for IMCR.

What other companies compete with Immunocore?

Other companies that are similar to Immunocore include Revolution Medicines, Relay Therapeutics, Immunovant, Krystal Biotech and Beam Therapeutics. Learn More about companies similar to Immunocore.

How do I contact Immunocore's investor relations team?

Immunocore's physical mailing address is 92 PARK DRIVE MILTON PARK ABINGDON, OXFORDSHIRE X0, OX14 4RY. The company's listed phone number is 44-12-3543-8600 and its investor relations email address is [email protected] The official website for Immunocore is www.immunocore.com. Learn More about contacing Immunocore investor relations.